The FDA approved the FineVision HP trifocal IOL for use in premium cataract surgery, according to a press release from BVI Medical.
“Cataract surgery has long lacked a widely proven trifocal option that delivers consistent visual quality across all distances,” Andy Chang, chief commercial officer of BVI, told Healio. “FineVision HP, third generation of FineVision trifocal technology, fills that gap with a design validated by more than 15 years of global clinical experience and over 1 million FineVision IOLs implanted, helping U.S. surgeons expand patient outcomes beyond the limitations of